Company: TXG
Filing Date: 2025-08-08
Form Type: 10-Q
Source: 0001770787-25-000051
Chunk: 5

Company: 10x Genomics, Inc.
Filing Date: 2025-08-08
Form: 10-Q
Item: Part I, Item 1
Chunk 5
---
Additional Paid-inCapitalAccumulatedDeficitAccumulatedOther ComprehensiveIncome (Loss)TotalStockholders’EquitySharesAmountBalance as of December 31, 2023119,095,362 $2 $2,025,890 $(1,284,420)$(429)$741,043 Issuance of Class A common stock related to equity awards605,487 — 1,638 — — 1,638 Stock-based compensation— — 36,129 — — 36,129 Net loss— — — (59,949)— (59,949)Other comprehensive loss— — — — (27)(27)Balance as of March 31, 2024119,700,849 2 2,063,657 (1,344,369)(456)718,834 Issuance of Class A common stock related to equity awards773,318 — 4,603 — — 4,603 Stock-based compensation— — 38,492 — — 38,492 Net loss— — — (37,897)— (37,897)Other comprehensive income— — — — 26 26 Balance as of June 30, 2024120,474,167 $2 $2,106,752 $(1,382,266)$(430)$724,058 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

6

10x Genomics, Inc.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

(In thousands)

Six Months Ended June 30,20252024Operating activities:Net income (loss)$180 $(97,846)Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:Stock-based compensation expense58,635 74,621 Depreciation and amortization15,837 18,165 Amortization of right-of-use assets3,628 4,229 Lease and asset impairment charges114 2,454 Realized loss on marketable securities— 1 Other(926)509 Changes in operating assets and liabilities:Accounts receivable37,917 23,638 Other receivables(68,484)(102)Inventory15,084 (15,134